{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:14:22Z","timestamp":1774570462875,"version":"3.50.1"},"reference-count":66,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00792","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T10:12:19Z","timestamp":1499681539000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Insights in Anaphylaxis and Clonal Mast Cell Disorders"],"prefix":"10.3389","volume":"8","author":[{"given":"David","family":"Gonz\u00e1lez-de-Olano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"\u00c1lvarez-Twose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report \u2013 Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1939-4551-7-9","article-title":"International consensus on (ICON) anaphylaxis","volume":"7","author":"Simons","year":"2014","journal-title":"World Allergy Organ J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000235323","article-title":"The high-affinity receptor for immunoglobulin E: a target for therapy of allergic diseases","volume":"94","author":"Kinet","year":"1991","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/0167-5699(93)90167-J","article-title":"Signal transduction by Fc receptors: the Fc epsilon RI case","volume":"14","author":"Beaven","year":"1993","journal-title":"Immunol Today"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.4049\/jimmunol.157.4.1693","article-title":"C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway","volume":"157","author":"Nilsson","year":"1996","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/eji.1830270925","article-title":"Human mast cells express functional TrkA and are a source of nerve growth factor","volume":"27","author":"Nilsson","year":"1997","journal-title":"Eur J Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0021-9258(18)54061-8","article-title":"Intracellular degradation of Fc gamma RIII in mouse bone marrow culture-derived progenitor mast cells prevents its surface expression and associated function","volume":"268","author":"Lobell","year":"1993","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4049\/jimmunol.152.2.811","article-title":"Fc gamma R-mediated endocytosis and expression of cell surface Fc gamma RIIb1 and Fc gamma RIIb2 by mouse bone marrow culture-derived progenitor mast cells","volume":"152","author":"Lobell","year":"1994","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/S0161-5890(02)00077-9","article-title":"Activation of human mast cells through the high affinity IgG receptor","volume":"38","author":"Tkaczyk","year":"2002","journal-title":"Mol Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/1521-4141(200111)31:11<3298::AID-IMMU3298>3.0.CO;2-U","article-title":"IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma","volume":"31","author":"Woolhiser","year":"2001","journal-title":"Eur J Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/90609","article-title":"Toll-like receptors: critical proteins linking innate and acquired immunity","volume":"2","author":"Akira","year":"2001","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1189\/jlb.70.6.977","article-title":"Toll-like receptor 4-mediated activation of murine mast cells","volume":"70","author":"McCurdy","year":"2001","journal-title":"J Leukoc Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.4049\/jimmunol.167.4.2250","article-title":"Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4","volume":"167","author":"Supajatura","year":"2001","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jaci.2006.04.015","article-title":"Molecular regulation of mast cell activation","volume":"117","author":"Rivera","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/87749","article-title":"gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation","volume":"2","author":"Castells","year":"2001","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s11882-014-0450-8","article-title":"Anaphylaxis as a clinical manifestation of clonal mast cell disorders","volume":"14","author":"Matito","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/9781444398595.ch29","article-title":"Diagnosis of adult mastocytosis: role for bone marrow analysis","volume-title":"Laboratory Hematology Practice","author":"Escribano","year":"2012"},{"key":"B23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/imt.11.44","article-title":"Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis","volume":"3","author":"Gonzalez-de-Olano","year":"2011","journal-title":"Immunotherapy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"B27","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood.V87.8.3117.bloodjournal8783117","article-title":"A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells","volume":"87","author":"Piao","year":"1996","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000237541","article-title":"c-kit mutation in a population of patients with mastocytosis","volume":"113","author":"Nagata","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A new c-kit mutation in a case of aggressive mast cell disease","volume":"96","author":"Pignon","year":"1997","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","article-title":"Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications","volume":"91","author":"Escribano","year":"1998","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cea.12369","article-title":"The presence of mast cell clonality in patients with unexplained anaphylaxis","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonzalez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.iac.2016.08.017","article-title":"Mastocytosis and anaphylaxis","volume":"37","author":"Schuch","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"B34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.iac.2015.01.010","article-title":"Mast cell activation syndromes presenting as anaphylaxis","volume":"35","author":"Akin","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"B35","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis \u2013 a single-centre experience","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"B37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-60327-951-2_16","article-title":"Anaphylaxis in mastocytosis","volume-title":"Anaphylaxis and Hypersensitivity Reactions","author":"Escribano","year":"2011"},{"key":"B38","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2013.06.020","article-title":"Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM","volume":"133","author":"Alvarez-Twose","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jaci.2012.12.1578","article-title":"Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis","volume":"132","author":"van Anrooij","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11882-015-0582-5","article-title":"Hymenoptera allergy and mast cell activation syndromes","volume":"16","author":"Bonadonna","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000096442","article-title":"Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome","volume":"142","author":"Sonneck","year":"2007","journal-title":"Int Arch Allergy Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2008.12.524","article-title":"Clinical, biological and molecular characteristics of mast cell activation disorders: a prospective study in 62 patients by the Spanish Network on Mastocytosis (REMA)","volume":"123","author":"\u00c1lvarez-Twose","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.12688\/f1000research.9565.1","article-title":"Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes","volume":"5","author":"Gonzalez-de-Olano","year":"2016","journal-title":"F1000Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.leukres.2014.11.029","article-title":"The impact of sensitive KIT D816V detection on recognition of indolent systemic mastocytosis","volume":"39","author":"De Matteis","year":"2015","journal-title":"Leuk Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/ACI.0000000000000280","article-title":"The difficult management of anaphylaxis in the elderly","volume":"16","author":"Gonzalez-de-Olano","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40413-015-0080-1","article-title":"2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines","volume":"8","author":"Simons","year":"2015","journal-title":"World Allergy Organ J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"55S","DOI":"10.1111\/1523-1747.ep12469049","article-title":"The treatment of mastocytosis: an overview","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000048189","article-title":"Mastocytosis: current treatment concepts","volume":"127","author":"Worobec","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1517\/21678707.2014.884922","article-title":"Management of adult mastocytosis","volume":"2","author":"Alvarez-Twose","year":"2014","journal-title":"Expert Opin Orphan Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/187152806775269303","article-title":"Current options in the treatment of mast cell mediator-related symptoms in mastocytosis","volume":"5","author":"Escribano","year":"2006","journal-title":"Inflamm Allergy Drug Targets"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient","volume":"65","author":"Douglass","year":"2010","journal-title":"Allergy"},{"key":"B56","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.anai.2013.08.014","article-title":"Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis","volume":"111","author":"Matito","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2007.05.011","article-title":"Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy","volume":"120","author":"Siebenhaar","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","article-title":"High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis","volume":"63","author":"Kontou-Fili","year":"2008","journal-title":"Allergy"},{"key":"B59","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jaip.2013.07.004","article-title":"Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome","volume":"1","author":"da Silva","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jaci.2006.01.046","article-title":"Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation","volume":"117","author":"Fahy","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.jaci.2006.04.005","article-title":"Anti-IgE as a mast cell-stabilizing therapeutic agent","volume":"117","author":"Chang","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-065X.2007.00519.x","article-title":"Differential release of mast cell mediators and the pathogenesis of inflammation","volume":"217","author":"Theoharides","year":"2007","journal-title":"Immunol Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/2162-3619-2-28","article-title":"Utility of hydroxyurea in mast cell activation syndrome","volume":"2","author":"Afrin","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000329218","article-title":"Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience","volume":"157","author":"Wimazal","year":"2012","journal-title":"Int Arch Allergy Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T11:14:30Z","timestamp":1692875670000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2017.00792"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00792","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]},"article-number":"792"}}